Quantcast
Last updated on April 16, 2014 at 7:10 EDT

Latest Sunitinib Stories

2014-02-20 04:21:29

WHIPPANY, N.J., Feb. 20, 2014 /PRNewswire/ -- Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga(®) (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases. The randomized, double-blind, placebo-controlled Phase III trial is designed to determine the effects of Stivarga as adjuvant treatment following surgical removal of liver metastases.(1) "Patients with more advanced colorectal cancer often...

2013-12-05 23:23:04

A recent study featured in the latest issue of The Oncologist shows that active smoking greatly diminishes patients’ chances of responding to chemotherapeutic treatment for renal cell carcinoma (RCC). The research team, jointly led by Dr. Michael Carducci from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD and Dr. Daniel Keizman from the Sackler School of Medicine at Tel Aviv University, conducted a retrospective analysis exploring the association of...

2013-11-11 08:28:34

Analysis of Phase 2 data evaluating induced memory T cell immunity following treatment with AGS-003 in combination with sunitinib presented at the 2013 Annual Meeting of the Society for Immunotherapy of Cancer (SITC). DURHAM, N.C., Nov. 11, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology...

2013-10-22 08:33:17

Designed to target advanced metastatic renal cell carcinoma, the study will determine the maximum tolerated dose of Debio 0932 in combination with everolimus LAUSANNE, Switzerland and LEXINGTON, Massachusetts, October 22, 2013 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a...

2013-10-17 08:22:50

Stivarga(®) (regorafenib tablets) receives expanded approval to include Gastrointestinal Stromal Tumours (GIST) after being approved for metastatic colorectal cancer earlier this year TORONTO, Oct. 17, 2013 /CNW/ - Bayer Inc. announced today Health Canada's expanded approval of Stivarga(®) (regorafenib tablets) to now include treatment of adult patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who have had disease progression on or intolerance...

2013-10-15 04:21:10

TUEBINGEN, Germany, October 15, 2013 /PRNewswire/ -- - immatics' lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015 - Funding secured within existing investor group immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a EUR34 million Series D financing round....

2013-09-23 12:25:42

ALBANY, New York, September 23, 2013 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies ResearchMoz announces that it has published a new study Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted...

2013-09-17 08:31:58

WHIPPANY, N.J., Sept. 17, 2013 /PRNewswire/ -- Bayer HealthCare announced today that data from the company's oncology portfolio, including Nexavar(®) (sorafenib) tablets, Stivarga(®) (regorafenib) tablets and Xofigo(®) (radium Ra 223 dichloride) injection will be presented at the 2013 European Cancer Congress (ECCO/ESMO/ESTRO), September 28 - October 1, in Amsterdam, Netherlands. These data include an oral presentation of a subanalysis from the Phase III trial of sorafenib in patients...

2013-08-30 04:20:40

WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., Aug. 30, 2013 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the European Commission has approved Stivarga® (regorafenib) tablets for the treatment of adult patients with metastatic colorectal cancer (mCRC). In September 2012, Stivarga was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-,...

2013-08-25 20:20:20

Attractive Addition to Amgen's Leading Oncology Portfolio and Pipeline THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 25, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash. Onyx...